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Abstract 
Context 
We compared the efficacy, safety and effect of 45-day isocaloric very-low-calorie ketogenic 
diets (VLCKDs) incorporating whey, vegetable or animal protein on the microbiota in patients 
with obesity and insulin resistance to test the hypothesis that protein source may modulate 
the response to VLCKD interventions. 
Subjects and Methods 
Forty-eight patients with obesity [19 males and 29 females, HOMA index ≥ 2.5, age 56.2±6.1 
years, body mass index (BMI) 35.9±4.1 kg/m2] were randomly assigned to three 45-day 
isocaloric VLCKD regimens (≤800 kcal/day) containing whey, plant or animal protein. 
Anthropometric indexes; blood and urine chemistry, including parameters of kidney, liver, 
glucose and lipid metabolism; body composition; muscle strength; and taxonomic 
composition of the gut microbiome were assessed. Adverse events were also recorded. 
Results 
Body weight, BMI, blood pressure, waist circumference, HOMA index, insulin, and total and 
LDL cholesterol decreased in all patients. Patients who consumed whey protein had a more 
pronounced improvement in muscle strength. The markers of renal function worsened 
slightly in the animal protein group. A decrease in the relative abundance of Firmicutes and 
an increase in Bacteroidetes were observed after the consumption of VLCKDs. This pattern 
was less pronounced in patients consuming animal protein. 
Conclusions 
VLCKDs led to significant weight loss and a striking improvement in metabolic parameters 
over a 45-day period. VLCKDs based on whey or vegetable protein have a safer profile and 
result in a healthier microbiota composition than those containing animal proteins. VLCKDs 
incorporating whey protein are more effective in maintaining muscle performance. 
Key words: Very low calorie ketogenic diet, VLCKD, obesity, whey proteins, vegetable proteins, 
animal proteins, intestinal microbiota, therapy 
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1. Introduction 
Obesity is strongly related to comorbidities, such as type 2 diabetes, inflammation, excess 
fat within the liver and pancreas, hypertension, and certain types of cancer (1, 2). Obesity 
management can delay the progression from prediabetes to type 2 diabetes (T2DM) and 
result in sustained remission of T2DM (3). 
For many individuals with obesity and prediabetes, weight loss produces beneficial 
outcomes in regard to glycemic control, lipids, and blood pressure, and more intensive 
weight loss maximizes these benefits (3, 4). Despite the agreement on the important role of 
diet in treating insulin resistance and T2DM, there is little consensus about the optimal diet 
and ideal dietary macronutrient ratio (5). Weight loss and improvement in glucose 
homeostasis, including diabetes remission, were seen both after the consumption of a low-
energy diet (825–853 kcal/day) with a carbohydrate content that exceeded 50% of total 
calories (3) and after the consumption of very low-calorie diets (VLCDs) (≤800 kcal/day) 
containing less than 30% carbohydrates/day (6). Recently, very-low-calorie ketogenic diets 
(VLCKDs) with <50 g of carbohydrates/day were found to be associated with greater weight 
loss along with amelioration of glycemic control in subjects with T2DM compared with the 
effects of a standard care nutritional intervention (7-11). In patients with obesity who did not 
have diabetes, the effects of VLCKDs were found to be powerful in reducing plasma insulin 
levels (5). Furthermore, the source of dietary protein while following an energy-restricted diet 
was associated with benefits in body weight (BW) maintenance, blood pressure, insulin and 
homeostasis model assessment of insulin resistance (HOMA-IR) (12). Epidemiological 
studies indicate that diets containing whey proteins and vegetable proteins protect against 
obesity, whereas diets characterized by increased meat consumption are associated with 
greater weight gain (13). The mechanisms underlying these effects are not known. 
Interactions with the intestinal microbiota (14), appetite regulation (15, 16), effects on insulin 
and incretin secretion (17-20), and palatability (19, 21) have been suggested as contributing 
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factors that deserve in-depth analysis (22). We conducted a prospective pilot study 
comparing the efficacy and safety of VLCKDs incorporating either whey, plant or animal 
protein on metabolic and body composition parameters and on the composition of the gut 
microbiota in a population of patients with obesity and insulin resistance. 
 
2 MATERIALS AND METHODS 
2.1 Study design and participants 
This was a prospective, open, nutritional intervention pilot study that enrolled patients with 
obesity and pharmacologically naïve insulin resistance among those attending the Center for 
the Study of Eating Disorders and Obesity, Department of Experimental Medicine, Section of 
Medical Pathophysiology, Food Science and Endocrinology of the University of Rome “La 
Sapienza”, Italy. We compared VLCKDs based on whey protein [(16 patients, whey protein 
group (WPG)], vegetable protein [(16 patients, vegetable protein group (VPG)] or animal 
protein [(16 patients, animal protein group (APG)]. Eligible patients were randomly assigned 
(in a 1:1:1 ratio) through automated allocation. The primary outcome measure was change in 
BMI. Key secondary outcomes were changes in lipids, glucose, insulin resistance as 
estimated by HOMA-IR, IGF-1, body composition, muscle strength and composition of the 
gut microbiota. Male and postmenopausal female outpatients were eligible. The inclusion 
criteria were as follows: stable BW in the previous 3 months, age between 50 and 70 years, 
BMI between 30 and 40 kg/m2, and HOMA-IR ≥ 2.5. The exclusion criteria were the following 
conditions either self-reported or derived from medical records or examination: 
hypersensitivity to components used in the protocol products; renal, cardiac, cerebrovascular 
or gastrointestinal diseases; psychiatric disturbances; hydroelectrolytic alterations; type 1 
diabetes; lack of informed consent; and bariatric surgery. Adverse events (AEs) were 
monitored throughout the treatment. This trial was registered at clinicaltrials.gov 
(NCT04019431). 
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2.2 Dietary interventions 
All patients followed a VLCKD [780 kcal/day, with the following composition in 
macronutrients, percentage of caloric intake and g/kg of ideal BW of proteins (derived by the 
BMI set at 25 kg/m2): carbohydrates 26 g (13.5%), olive oil 20 g plus 15 g of lipids from other 
sources (40.4%), protein 90 g (46.1%, 1.2 -1.4 g/kg)] for 45 days. The amount of protein was 
within the proposed essential composition of total diet replacements for weight control and 
was adjusted for the patients with overweight or obesity (23). WPG and VPG patients were 
given five meals/day [timing was at main meals (8 a.m., 1.00 p.m. and 8.00 pm), mid-
morning and mid-afternoon] containing whey protein (WPG) or vegetable protein derived 
from soya, green peas or cereals and one serving of vegetables with a low glycemic index at 
lunch and dinner (VPG). Patients in the APG were given five meals/day containing natural 
animal protein (meat, fish, eggs). Supplements containing vitamins, minerals and omega-3 
fatty acids were provided in accordance with international recommendations (EFSA 2017, 
https://doi.org/10.2903/sp.efsa.2017.e15121). The diets were prepared by New Penta s.r.l. 
(Cuneo, Italy) following the indications of nutritionists and were delivered in preassembled 
boxes. 
Participants received counseling by physicians and nutrition experts at baseline (T0) 
and every two weeks up to day 45 (T45); dietary compliance was also assessed. 
Participants were encouraged to exercise for 30 minutes at least 3 times weekly, but 
no formal exercise program or incentives were provided. 
2.3 Anthropometric assessment 
BW, height, systolic and diastolic blood pressure (BP), waist circumference (WC), 
thigh circumference (TC) and hip circumference (HC) were measured at T0 and 
every two weeks. Anthropometric measurements were recorded after an overnight 
fast under resting conditions using calibrated equipment. BW was measured using a 
balance-beam scale (Seca GmbH & Co). Systolic and diastolic blood pressure were 
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measured using a mercury-gravity manometer. Height was rounded to the closest 
0.5 cm. BMI was calculated as weight divided by squared height in meters (kg/m2). 
WC was measured midway between the costal arch and the iliac crest, HC was 
measured at the symphysis-greater trochanter level to the closest 1.0 cm, and TC 
was measured directly below the gluteal fold of the right thigh. 
2.4 Blood and urine chemistry 
Blood count (ADVIA 2120i Hematology System, Siemens Healthcare s.r.l., Italy), 
electrolytes [chloride, potassium and sodium (indirect ion-selective electrode 
potentiometry), calcium and magnesium (colorimetric assay)], glucose (enzymatic 
colorimetric assay), insulin (electrochemiluminescence immunoassay), lipids 
[(triglycerides, total, HDL and LDL cholesterol) (enzymatic colorimetric assay)], total 
protein and albumin (capillary system), C-reactive protein (CRP) 
(immunoturbidimetric assay), erythrocyte sedimentation rate (ESR) (capillary 
photometric assay), plasma creatinine (kinetic colorimetric compensated  aff  
method), blood urea nitrogen (BUN), uric acid, alanine transferase (ALT) and 
aspartate transaminase (AST) (enzymatic colorimetric assay), and estimated 
glomerular filtration rate (eGFR) were determined at baseline and T45. All analyses 
were performed on a COBAS 6000 (Roche Diagnostics, Risch-Rotkreuz, 
Switzerland) and on CapillarysR Systems (Sebia, Evry, France). 
The hepatic steatosis index (HSI), a noninvasive screening tool for hepatic steatosis, 
was calculated according to Lee et al. (24). IGF-1 plasma levels were measured 
after an overnight fast using commercial ELISA assay kits (R&D Systems, Inc., 
Minneapolis, MN, USA). Insulin resistance was determined using HOMA-IR (25). 
The semiquantitative concentration of acetoacetic acid was measured in the first 
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morning urine at baseline and every week until the end of the study by the patients 
(Ketur-Test, Accu-Chek, Roche Diagnostics, Italy). 
2.5 Dual-energy X-ray absorptiometry measurement (DEXA) 
Body composition, total and regional body fat mass and fat-free mass were 
measured by DEXA (Hologic 4500, Bedford, MA, USA) at baseline and at the end of 
the trial. Trunk fat was defined as the adipose tissue localized within the region 
below the chin, delineated by vertical lines within the left and right glenoid fossae 
bordering laterally to the ribs and by the oblique lines that cross the femoral necks 
and converge below the pubic symphysis. 
2.6 Muscular strength 
Handgrip strength (HG) was measured with a digital dynamometer (DynEx, Akern, 
Pontassieve, FI, Italy) at T0 and T45 with the patients seated, shoulder adducted 
and forearms resting flat on the chair arms. Before starting, patients were asked to 
squeeze the dynamometer as hard as possible for at least 3 seconds. Three 
measurements were repeated with both the dominant and nondominant arms. The 
highest value measured was recorded. 
2.7 Taxonomic composition of the gut microbiome 
Fecal sampling was performed using a sterile swab (FLmedical, Italy) and tubes 
(Starlab Group, Italy) in the morning of the day of initiating the VLCKD and at T45; 
the samples were put on ice immediately after collection, brought to the hospital 
within 2 h, and stored at −80 °C. The samples were transferred to the laboratory on 
dry ice within 24 h of collection and stored at −80 °C until DNA extraction. DNA was 
extracted using the Cador Pathogen 96 QIAcube HT Kit (Qiagen srl, Italy) with lysis 
step modification according to the Mobio PowerFecal kit (Qiagen). The V3-V4 
regions of the 16S ribosomal RNA gene were amplified using the Illumina tailed 
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primers Pro341F (5′-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-
CCTACGGG AGGCAGCA-3′) and Pro805R (5′-
GTCTCGTGGGCTCGGAGATGTGTATAAGAGA CAG-
GACTACNVGGGTATCTAATCC-3′) using Platinum Taq (Thermo Fisher Scientific 
Inc, USA) to conduct PCR (94 °C for 2 min, followed by 25 cycles at 94 °C for 30 s, 
55 °C for 30 s, and 68 °C for 30 s, and a final extension at 68 °C for 7 min). PCR 
amplicons were purified with Agencourt AMPure XP Beads 0.8X (Beckman Coulter, 
Inc., CA, USA) and amplified following the Nextera XT Index protocol (Illumina, Inc., 
CA, USA). The purified amplicons were normalized by SequalPrep™ Normalization 
Plate Kit (Thermo Fisher Scientific Inc.) and multiplexed. The pool was purified with 
1X Magnetic Beads Agencourt XP (Beckman Coulter, Inc.) loaded on the MiSeq 
System (Illumina, Inc.) and sequenced following the V3 - 300PE strategy. The 
bioinformatic analysis was performed by Qiime2 (26). Raw reads were first trimmed 
by applying Cutadapt to remove residual primer sequences and then processed with 
DADA2 plug-in to perform the denoising step (27, 28). DADA2 was run with default 
parameters except for the truncation length: forward and reverse reads were 
truncated at 270 and 260 nucleotides, respectively. The resulting amplicon sequence 
variant (ASV) sequences were filtered out by applying a 0.005% frequency threshold 
to discard singletons and very rare sequences. Greengeens v.13-8 and Silva v.132 
databases were used to associate the taxonomy to the remaining ASVs. 
2.8 Questionnaires 
Adherence to the dietary interventions was evaluated through a daily food diary. Safety was 
monitored throughout the trial based on the reported AEs either collected spontaneously or 
actively assessed by the investigators. Quality of life was assessed through the SF-36 
questionnaire every two weeks. Vivacity, agitation, sadness, calmness, energy, 
discouragement, happiness, and satiety were evaluated using a 5-point scale. 
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2.9 Data management and statistical methods 
Data are expressed as the mean values ± SDs or percentages where appropriate. 
Comparisons between groups were evaluated using Student’s t test. Differences between 
groups were tested by ANOVA, and for differences 0-45, an ANCOVA model was used 
when a significant group effect was observed. A Tukey post hoc test was used for multiple-
comparison purposes in the case of F significant values. The number of subjects was 
identified considering the number of subjects generally included in similar published pilot 
studies (29-32). Assuming a power of 0.80 and alpha of 0.05, 48 participants (total sample 
size, 16 participants in each of 3 groups) were considered appropriate to highlight an effect 
size of 0.46 (high). Differences were considered statistically significant when P was ≤0.05. 
Since this was a pilot study, we also reported values with P<0.1 as "trending towards 
significance". Statistical analysis was carried out using R-package version 3.6.3. 
2.10 Ethical aspects 
The study protocol was approved by the Ethics Committee of the University of Rome “La 
Sapienza” (code 3920) and was conducted in accordance with the Declaration of Helsinki 
and Good Clinical Practice. All patients were informed about the possible risks and benefits 
of the proposed interventions and provided written consent. 
 
3 RESULTS 
We screened 350 patients with obesity for eligibility from January 2019 to June 2019. We 
enrolled and randomized 48 participants. Sixteen patients were allocated to the VLCKD with 
whey protein group (WPG), 16 to the VLCKD with vegetable protein group (VPG), and 16 to 
the VLCKD with animal protein group (APG) (Fig. 1). All the participants were followed up to 
the completion of the study. The baseline characteristics of the patients were similar 
between groups and are summarized in table 1. Compliance was comparable in all groups. 
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Urine acetoacetic acid, reflecting ketosis, increased significantly from baseline to the end of 
the VLCKD interventions (table 1), and a plateau value was reached after 7 days in all 
groups (data not shown). 
We recorded a significant reduction in initial BW both in the WPG and the VPG at T45. A 
reduction in BW was also observed in the APG (-6.4±2.4 kg compared to baseline, range -
2.0/-11.1 kg, average percent BW loss -6.5%), although it did not reach statistical 
significance. BMI followed the same pattern, with the exception that the improvement in BMI 
was statistically significant in the APG as well. Significant reductions in WC and systolic and 
diastolic blood pressure were recorded in all groups. HC and TC reductions were observed 
in all groups and reached significance in the VPG and the APG and the WPG and the VPG, 
respectively. 
A significant reduction in fasting glycemia, fasting insulin and HOMA-IR was observed in all 
groups, with the exception of fasting glycemia in the VPG. Circulating IGF-1 levels increased 
in the WPG and decreased in the VPG. The increase in IGF-1 seen in the APG was not 
statistically significant. 
A decreasing trend in total fat and trunk fat mass was consistently recorded, although the 
significance was seen only for trunk fat mass in the WPG and the VPG. A relative increase 
in the percentage of lean mass was also seen consistently. Electrolytes (data not shown) 
and liver function tests did not change during the study within groups. Small, nonsignificant 
variations in plasma creatinine values were observed in all groups. Of note, in the APG, 
blood urea nitrogen and uric acid increased while eGFR decreased significantly compared 
with baseline. Urinary pH values varied within the normal reference intervals (data not 
shown). At the baseline visit, no ketosis was recorded. The mean values of urinary 
acetoacetic acid increased from T0 to T45 in all groups (table 1). 
The HSI was slightly reduced at T45; however, the difference was significant only for VPG. 
All groups experienced a profound reduction in total cholesterol, LDL cholesterol and 
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triglycerides. Despite a strong improvement in the inflammatory markers ESR and CRP, 
changes in these measures did not show statistical significance. HG did not change during 
the observation period in any of the groups. 
The P values of multiple comparisons of delta percent variations in the measured 
parameters between groups that were statistically significant are shown in table 2. No 
differences were seen for the majority of parameters, with the exception of IGF-1, creatinine, 
eGFR, blood urea, uric acid and HG, whose variations differed between groups. Figure 2 
shows the box plot of the within-group percent change values from baseline. Although the 
variations remained within the normal range, the group of patients who consumed a VLCKD 
containing animal protein (APG) showed an increase in creatinine levels and a significant 
reduction in eGFR compared to the same parameters of the other two treatment groups. The 
delta percent increase in BUN was more pronounced in the WPG and the APG, while uric 
acid increased more in the VPG. HG was maintained to a greater extent in the WPG than in 
the VPG. The delta percent increase in IGF-1 values was more pronounced in the WPG and 
the APG than in the VPG. 
The dominant phyla in the fecal samples of the patients at T0 were Firmicutes, 
Bacteroidetes, Proteobacteria, Verrucomicrobia, Fusobacteria, and Actinobacteria (Fig. 3A). 
The relative abundance of Firmicutes was significantly diminished, and that of Bacteroidetes 
increased proportionally 45 days after the initiation of the VLCKDs (Fig. 3B). The mean 
relative abundance of Proteobacteria also increased, while that of Actinobacteria decreased 
(data not shown). The abundance of the two predominant bacterial divisions (Firmicutes and 
Bacteroidetes) was almost superimposable in the three dietary intervention groups of 
patients at baseline, with no differences according to multiple comparison (Fig. 4). Over time, 
the relative abundance of Bacteroidetes increased, and the abundance of Firmicutes 
significantly decreased, irrespective of diet type, with the only exception in the VPG, in which 
the increase in Bacteroidetes did not reach statistical significance (Fig. 4). To verify whether 
the different protein sources in the VLCKDs could influence the variation in the abundance of 
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Firmicutes and Bacteroidetes, a two-way ANOVA test was performed. The increase in 
Bacteroidetes and the decrease in Firmicutes were influenced by the protein composition of 
the diets. In particular, whey protein and vegetable protein were more potent in reducing the 
percentage of Firmicutes than the dietary intervention incorporating animal protein. 
Regarding the Bacteroidetes gut microbiota content, a significant difference was only 
observed between the individuals exposed to the diets incorporating whey protein and 
vegetable protein, with the VLCKD containing whey protein exhibiting a more potent ability to 
increase the percentage of total sequences of Bacteroidetes. 
The AEs were mild; in fact, none of the patients dropped out of the study, and the 
differences between the diet interventions were negligible (table 3 shows the most frequent 
side effects and the number of participants reporting them). During ketosis, the intragroup 
variation as well as the intergroup variation in the quality of life scores did not change (data 
not shown). 
 
4 DISCUSSION 
Our data show that a 45-day-long VLCKD causes a profound reduction in BW and improves 
glycemic control, lipid metabolism and arterial pressure in patients with obesity and insulin 
resistance. The VLCKD is safe and well tolerated; the gut microbiota composition is 
influenced by the VLCKD, and the source of dietary protein modulates the variation in the 
gut microbiota caused by the VLCKD. Whey protein intake contributes more substantially to 
the preservation of muscle performance. 
These results provide important implications. First, VLCKDs may hold promise as a strategy 
to simultaneously improve glycemic control while facilitating profound weight loss in patients 
with insulin resistance. All individuals who consumed VLCKDs showed a decrease in fasting 
plasma glucose, insulin and HOMA-IR. Of note, no episodes of hypoglycemia were 
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observed. Numerous studies on VLCKDs have shown diabetes improvement and remission 
(8, 9, 11, 33). Here, we show that this pattern applies to individuals with insulin resistance as 
well. We hypothesize that the improvement in carbohydrate metabolism might correlate with 
both weight loss and low sugar content, although additional mechanisms cannot be excluded 
(34). The short duration of our intervention prevents the assessment of the durability of the 
effect. 
An important concern with low carbohydrate diets is the potential negative impact on lipid 
metabolism due to the increased proportion of calories coming from fat. Clearly, this does 
not apply to a 45-day VLCKD, for which the daily lipid intake is still low, as can be inferred by 
the profound reduction in the circulating cholesterol and triglyceride levels measured in our 
patients. Many other mechanisms may contribute to the reduction in circulating lipids, such 
as the improvement in insulin resistance with positive effects on lipid metabolism through the 
action on HMG-CoA reductase and striking effects on lipoprotein size and subclass particle 
concentrations (35). Moreover, it has been reported that even high-fat ketogenic diets are 
capable of ameliorating nonalcoholic fatty liver disease through de novo lipogenesis 
inhibition and fatty acid oxidation induction, leading to weight loss and reduced hepatic fat 
content. It is therefore unsurprising that serum triglycerides, well-established markers of liver 
fat, are almost invariably reduced upon the adoption of any kind of ketogenic diet (36). 
Many studies have shown that dietary protein content may play a role in weight management 
(37-39). Much less is known about the importance of the sources from which these proteins 
are derived (40). In the face of significant variations in the anthropometric measures 
between T0 and T45 within each group, the intake of different kinds of protein was not 
associated with meaningful changes in BW, WC, BMI or the remaining anthropometric 
parameters among groups. Some differences that might have clinical significance reflect the 
proportion of lean and fat mass in different body regions. The loss of trunk fat mass was less 
pronounced in the group of patients who consumed animal protein. However, the between-
group comparison of trunk fat content did not reveal a significant difference. 
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Analogous to a previous report (32), crude HG did not vary significantly during our dietary 
intervention. This is notable due to the well-known cardiovascular advantages of maintaining 
muscle strength (41-42). Interestingly, the individuals fed whey protein preserved their HG 
strength to a greater extent than in the vegetable protein-fed group. Whether this is due to 
the higher relative increase in IGF-1 levels associated with whey protein consumption is 
unclear. Our data are in line with the reported association between protein intake, largely 
attributable to milk intake, and circulating IGF-1 levels, an association that has been related 
to muscle strength (43-44). Our evidence is purely associative, and many other 
mechanisms, including neural mechanisms, learning effects, and improvement in the actin-
myosin machinery, among others, may explain this finding. Furthermore, our measurements, 
although accurately conducted, suffer from the variation in current methods of assessing grip 
strength (45); thus, an analysis of a larger sample is warranted. 
The intestinal microbiota is relatively stable throughout adult life (46-48). Each individual has 
his or her own unique microbial community whose profile is stable over time. However, much 
is still unknown regarding how stable the microbiota is to perturbations, such as those arising 
from antibiotics, diet and the immune system. KDs influence the taxonomic and functional 
composition of the gut microbiota with mixed contradictory results (49). We observed a 
pattern in the variation in the microbiota that resembled that in children affected by refractory 
epilepsy treated with KDs, with increased amounts of Bacteroides and decreased amounts 
in Firmicutes (50,51). Moreover, we found divergent responses to VLCKDs containing 
protein from different sources with substantial effects on the Firmicutes-to-Bacteroidetes 
ratio. Recent evidence suggests that the quality of dietary protein may impact the gut 
environment, shaping the microbiota and the host-microbe (co)metabolic pathways and 
products and linking protein-dependent changes in the obese gut microbiota (52, 53). The 
gut microbiota composition in mice (54), rats (55), and piglets (56) revealed divergent 
responses to diets containing protein from different sources. Although the prospect of health-
interpretable microbiota data is exciting (57,58), and despite a decade of research 
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establishing a strong association between the gut microbiota and various diseases, including 
obesity and diabetes, in humans a causal relationship and the underlying mechanism remain 
unknown (59-61). The strongest effect of the VLCKD containing whey protein in reducing 
Firmicutes and increasing Bacteroidetes compared with the vegetable- and animal-
containing VLCKDs observed here warrants further investigation. 
The profound metabolic effects associated with VLCKDs were observed in the absence of 
serious AEs that were previously associated with VLCKD interventions (8,49,62,63). Quality 
of life score variations were negligible. 
Regarding the potential issues of our pilot study, the number of subjects enrolled was small, 
although sufficient, to appreciate the variations induced by VLCKDs. The short duration is a 
further limitation together with the lack of follow-up. Moreover, the measurement of capillary 
blood concentration of beta hydroxybutyrate would have been a more accurate method of 
ketosis assessment than the urinary acetoacetate semiquantitative determination used in 
this study for technical reasons. However, the fundamental objectives that our study had set 
were achieved, and the additional information obtained will certainly lead to further 
investigation. 
In summary, these data show that a 45-day-long VLCKD is safe and quickly reduces weight 
and fasting glycemia in patients with obesity and insulin resistance. The investigated protein 
sources did not differ ntially impact anthropometric or metabolic parameters under the acute 
conditions of the intervention in our experimental design. However, whey proteins and 
vegetable proteins showed a safer profile and directed the intestinal microbiota towards a 
healthier composition. 
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Figure legends 
 
Figure 1. Flow diagram of the study. A total of 350 individuals were screened. The subjects 
enrolled were randomized to either a VLCKD dietary intervention group with whey protein, a 
VLCKD dietary intervention group with vegetable protein or a VLCKD dietary intervention 
group with animal protein. 
 
Figure 2. Box plot of pooled ranking of all observed relative differences (% variation vs. 
basal values) from day 0 to day 45 in BUN, creatinine, eGFR, uric acid, HG, and IGF1 
values in the WPG, the VPG and the APG. The P values of the parameters plotted are 
shown in table 2. 
 
Figure 3. Correlation between VLCK dietary interventions and gut microbial ecology. (A) 
Relative abundance of bacterial phyla in each sample among each treatment group (n=7) at 
time 0 and after 45 days of VLCKD dietary intervention (group 1, VLCKD with whey protein; 
group 2, VLCKD with vegetable protein; group 3, VLCKD with animal protein). (B) Relative 
abundance of Bacteroidetes and Firmicutes. For each time point, values from all available 
samples were averaged (n was 21 per time point). Mean values ± SDs are plotted. *** = 
p<0.0001 
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Figure 4. Effect of 45-day VLCKD dietary interventions with whey protein (white bars), 
vegetable protein (green bars) and animal protein (red bars) on the relative abundance of 
Firmicutes and Bacteroidetes. For each time point, values from all available samples were 
averaged (n was 7 per time point). Mean values ± SDs are plotted. * = p<0.017; ** = 
p<0.0023; *** = p<0.001 
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Table 1. Participant characteristics at baseline (T0) and after 45 days (T45) of VLCKD consumption (whey 
protein group, WPG; vegetable protein group, VPG; animal protein group, APG) 
  WPG   VPG   APG   
 T0 T45 P  T0 T45  P  T0 T45  P  
BW (kg) 102.02 ± 
12.04 
94.05 ± 
11.43 
0.03
2 
102.10 ± 
12.36 
94.08 ± 
11.92 
0.041 98.36 ± 
14.49 
91.72 ± 
14.48 
0.106 
BMI (kg/m2) 35.8 ± 5.0 32.6 ± 4.8 0.03
5 
36.1 ± 4.3 32.9 ± 4.0 0.020 35.7 ± 3.7 32.8 ± 3.7 0.016 
WC (cm) 110.0 ± 9.4 102.8 ± 8.4 0.01
4 
108.2 ± 8.5 102.5 ± 7.6 0.031 105.3 ± 
9.1 
99.1 ± 10.2 0.040 
HC (cm) 123.6 ± 
12.1 
117.9 ± 
12.2 
0.09
8 
123.3 ± 9.3 117.9 ± 8.4 0.049 122.5 ± 
10.6 
116.1 ± 
10.3 
0.047 
TC (cm) 63.6 ± 5.3 59.7 ± 5.2 0.02
2 
64.1 ± 5.3 60.5 ± 5.9 0.043 65.4 ± 7.2 62.1 ± 6.6 0.091 
Arm circumference 
(cm) 
36.6 ± 3.9 34.6 ± 3.7 0.07
2 
36.3 ± 3.7 34.5 ± 3.4 0.083 37.7 ± 3.0 35.6 ± 2.9 0.029 
Systolic BP (mmHg) 132 ± 10 124 ± 13 0.03
2 
131 ± 8 121 ± 10 0.005 129 ± 9 121 ± 16 0.036 
Diastolic BP (mmHg) 78 ± 11 70 ± 9 0.02
0 
78 ± 10 72 ± 10 0.030 78 ± 10 71 ± 9 0.014 
Fasting glycemia 
mg/dL  
108.1 ± 
22.3 
94.1 ± 11.4 0.01
7 
106.5 ± 
17.6 
100.9 ± 
17.6 
0.193 99.7 ± 
12.9 
92.6 ± 9.2 0.042 
Fasting insulin  
(μIU/ml) 
25.0 ± 18.9 8.5 ± 4.1 0.00
1 
19.4 ± 7.4 8.3 ± 4.7 0.000 17.7 ± 8.7 6.8 ± 4.1 0.000 
HOMA-IR (ng/ml) 4.15 ± 1.34 2.1 ± 1.2 0.00
4 
5.1 ± 2.0 2.1 ± 1.2 0.000 4.05 ± 
1.72 
1.6 ± 1.1 0.000 
IGF-1 (ng/ml) 141.4 ± 
15.91 
167.46 ± 
43.15 
0.01
8 
159.82 ± 
19.25 
116.52 ± 
22.05 
0.000 132.88 ± 
26.92 
148.86 ± 
32.15 
0.160 
Creatinine (mg/dl) 0.90 ± 0.30 0.79 ± 0.22 0.12 0.78 ± 0.17 0.78 ± 0.15 0.465 0.80 ± 
0.16 
0.86 ± 0.19 0.163 
BUN (mg/dl) 39.0 ± 12.5 38.5 ± 13.9 0.46
6 
40.0 ± 13.1 37.4 ± 12.1 0.281 39.3 ± 6.8 48.0 ± 14.4 0.019 
eGFR (ml/min) 131.9 ± 
42.9 
136.6 ± 
56.1 
0.39
5 
146.4 ± 
33.3 
131.4 ± 
26.8 
0.091 134.8 ± 
33.2 
115.6 ± 
30.2 
0.049 
Proteins (g/L) 74.3 ± 4.0 71.8 ± 2.9 0.02
8 
75.0 ± 3.5 74.0 ± 4.1 0.237 74.3 ± 4.4 72.2 ± 3.5 0.070 
Albumin (g/L) 44.13 ± 
2.43 
43.71 ± 
2.90 
0.32
8 
44.55 ± 
2.76 
43.98 ± 
2.69 
0.283 44.68 ± 
2.71 
44.22 ± 
1.91 
0.293 
AST (U/L) 23.8 ± 13.0 19.9 ± 5.8 0.14
6 
25.3 ± 13.2 26.8 ± 14.0 0.385 19.8 ± 4.7 19.9 ± 3.7 0.450 
ALT (U/L) 31.1 ± 15.4 24.0 ± 9.3 0.06
2 
35.0 ± 24.0 35.5 ± 26.9 0.479 23.8 ± 7.0 21.6 ± 4.9 0.151 
HSI  44.0 ± 5.1 41.6 ± 5.4 0.10
1 
44.1 ± 5.4 40.9 ± 5.2 0.049 44.3 ± 4.4 42.1 ± 4.1 0.077 
Uric acid (mg/dl) 5.4 ± 1.1 5.1 ± 1.4 0.25
7 
5.2 ± 1.0 5.8 ± 1.1 0.072 4.9 ± 1.0 5.6 ± 0.8 0.021 
CRP (g/L) 4700 ± 
6740 
2662 ± 
2414 
0.13
2 
7050 ± 
5959 
5913 ± 
6435 
0.307 5156 ± 
4820 
4087 ± 
3383 
0.237 
ESR (mm/h) 26.8 ± 16.0 28.5 ± 15.8 0.37
9 
28.0 ± 17.9 25.7 ± 17.1 0.357 28.8 ± 
15.8 
26.1 ± 12.1 0.292 
Total cholesterol 
(mg/dl) 
214.8 ± 
31.5 
166.2 ± 
43.6 
0.00
1 
220.9 ± 
51.6 
170.7 ± 
36.3 
0.002 226.9 ± 
32.7 
191.2 ± 
34.2 
0.003 
LDL cholesterol 
(mg/dl) 
132.8 ± 
30.8 
100.8 ± 
38.4 
0.00
8 
136.1 ± 
41.3 
97.5 ± 32.3 0.004 143.9 ± 
25.8 
118.5 ± 
23.1 
0.003 
Triglycerides (mg/dl) 131.0 ± 
44.9 
94.6 ± 32.0 0.00
7 
170.1 ± 
126.9 
117.6 ± 
42.7 
0.069 124.25 ± 
58 
82.25 ± 
33.32 
0.009 
HDL cholesterol 
(mg/dl) 
51.7 ± 12.3 46.1 ± 7.5 0.07
2 
51.2 ± 12.8 49.0 ± 9.5 0.298 57.9 ± 
23.7 
56.2 ± 18.0 0.408 
Urine acetoacetic 
acid (mg/dL) 
1.8 ± 0.8 56.3 ± 31.3 0.00
0 
1.8 ± 0.7 41.1 ± 15.4 0.000 1.6 ± 0.7 44.8 ± 15.3 0.000 
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Total fat (kg) 36.74 ± 
10.83 
31.92 ± 
10.19 
0.10
2 
37.40 ± 
7.77 
32.00 ± 
7.51 
0.081 37.00 ± 
8.23 
32.85 ± 
8.88 
0.094 
Total lean (kg) 62.95 ± 
9.04 
59.93 ± 
7.66 
0.15
8 
62.32 ± 
1.04 
59.70 ± 
10.02 
0.246 57.24 ± 
9.21 
56.59 ± 
12.18 
0.434 
Total fat (%) 35.71 ± 
8.38 
33.33 ± 
8.33 
0.21
3 
36.69 ± 
6.46 
34.06 ± 
6.82 
0.144 37.75 ± 
6.87 
35.89 ± 
8.04 
0.247 
Total lean (%) 62.01 ± 
8.01 
64.13 ± 
7.88 
0.43
8 
60.96 ± 
6.29 
63.41 ± 
6.59 
0.072 58.57 ± 
7.60 
61.63 ± 
7.99 
0.026 
Trunk fat (kg) 18.40 ± 
5.54 
15.43 ± 
5.01 
0.02
2 
18.69 ± 
3.36 
15.96 ± 
3.24 
0.016 17.43 ± 
3.27 
15.46 ± 
3.80 
0.065 
HG (kg) 32.47 ± 
7.73 
34.45 ± 
7.34 
0.23 30.13 ± 
6.99 
31.01 ± 
6.92 
0.36 32.64 ± 
9.04 
34.03 ± 
9.25 
0.33 
 
 
 
 
 
 
Abbreviations: BW, body weight; BMI, body mass index; WC, waist circumference; HC, hip 
circumference; TC, thigh circumference; BP, blood pressure; HOMA-IR, homeostasis model 
assessment- insulin resistance; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration 
rate; AST, aspartate transaminase; ALT, alanine transferase; HSI, hepatic steatosis index; CRP, C-
reactive protein; ESR, erythrocyte sedimentation rate; HG, handgrip strength. Values in bold 
indicate statistically significant results (P≤0.05). 
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Table 2. Between-group (ANCOVA) and within-group (ANOVA) P values of the percent change from baseline of the 
parameters with a significant group effect measured after 45 days of VLCKD consumption (whey protein group, 
WPG; vegetable protein group, VPG; animal protein group, APG).  
 
 Between groups WPG vs VPG WPG vs APG A PG vs VPG 
IGF-1  0.0000 0.0000 0.5697 0.0011 
Creatinine  0.0010 0.0696 0.0006 0.2004 
BUN 0.0019 0.2281 0.0973 0.0013 
eGFR 0.0016 0.0334 0.0013 0.4690 
Uric acid  0.0112 0.0533 0.0128 0.8316 
HG  0.0040 0.0027 0.1351 0.2652 
Abbreviations: BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; HG, handgrip strength; ALM, 
appendicular lean mass; DALM, dominant arm lean mass. 
Values in bold indicate statistically significant results (P≤0.05) and values "trending towards significance" (P<0.1). 
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Table 3. Adverse events during the nutritional interventions (WPG, VLCKD 
incorporating whey protein; VPG, VLCKD incorporating vegetable protein; APG, 
VLCKD incorporating animal protein) recorded 15 days (T15) and 45 days (T45) 
after the start of the diets. Number (percentage) of participants reporting an adverse 
event. 
 WPG VPG APG 
 T15  T45  T15  T45  T15  T45  
constipation 2 (12.5) 4 (25) 2 (12.5) 4 (25) 2 (12.5) 6 (37.5) 
diarrhea 1 (0.6) 1 (0.6) 3 (18.7) 2 (12.5) 1 (0.6) 2 (12.5) 
cramps 1 (0.6) 1 (0.6) 2 (12.5)  1 (0.6) 1 (0.6) 1 (0.6) 
nausea 2 (12.5) 2 (12.5) 2 (12.5) 1 (0.6) 1 (0.6) 1 (0.6) 
fatigue 1 (0.6) 1 (0.6) 3 (18.7) 2 (12.5) 2 (12.5) 1 (0.6) 
hunger 3 (18.7) 3 (18.7) 2 (12.5) 2 (12.5) 3 (18.7) 2 (12.5) 
headache 4 (25) 1 (0.6) 2 (12.5) 1 (0.6) 2 (12.5) 2 (12.5) 
dizziness 2 (12.5) 2 (12.5) 2 (12.5) 1 (0.6) 1 (0.6) 1 (0.6) 
insomnia 1 (0.6) 1 (0.6) 1 (0.6) 2 (12.5) 2 (12.5) 2 (12.5) 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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